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Mutations in COL6A1, COL6A2 and COL6A3 genes result in collagen VI myopathies: Ullrich congenital muscular dystrophy
(UCMD), Bethlem myopathy (BM) and intermediate phenotypes. At present, none of the existing diagnostic techniques for evaluating
collagen VI expression is quantitative, and the detection of subtle changes in collagen VI expression remains challenging.
We investigated ﬂow cytometry analysis as a means of quantitatively measuring collagen VI in primary ﬁbroblasts and compared this
method with the standard method of ﬁbroblast collagen VI immunohistochemical analysis. Eight UCMD and ﬁve BM molecularly
conﬁrmed patients were studied and compared to ﬁve controls.
Flow cytometry analysis consistently detected a reduction of collagen VI of at least 60% in all UCMD cases. In BM cases the levels of
collagen VI were variable but on average 20% less than controls.
Flow cytometry analysis provides an alternative method for screening for collagen VI deﬁciency at the protein level in a quantitative,
time and cost-eﬀective manner.
 2011 Elsevier B.V.
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Collagen VI is an ubiquitous extracellular matrix
protein composed of three diﬀerent peptide chains,
a1(VI), a2(VI) and a3(VI), encoded by the COL6A1,
COL6A2 and COL6A3 genes. After several intracellular
assembly steps, tetramers are secreted from the cell to the
extracellular matrix where they assemble into beaded
microﬁlaments [1,2]. Further collagen VI chains, a4(VI),0960-8966 2011 Elsevier B.V.
doi:10.1016/j.nmd.2011.08.006
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Open access under CC BY license.a5(VI) and a6(VI) have been identiﬁed and contribute to
the complexity of collagen VI function in the extracellular
matrix [3,4].
Mutations in any of the three collagen 6A genes
COL6A1, COL6A2 and COL6A3 result in Ullrich congen-
ital muscular dystrophy (UCMD), Bethlem myopathy
(BM) or phenotypes intermediate between UCMD and
BM, characterised by a combination of distal laxity, prox-
imal muscle weakness and joint contractures [5,6]. It was
initially thought that autosomal dominant mutations in
the collagen VI genes were associated with the milder
BM variant whilst the more severe variant of UCMD
was attributed to autosomal recessive inheritance [7]. More
recently, however, it has become clear that a signiﬁcant
proportion of UCMD patients carry de novo dominant
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have been described [8–11]. Furthermore, a recent paper
suggested that myosclerosis myopathy should be regarded
as a collagen VI related disorder. Two myosclerosis myop-
athy patients (siblings from a consanguineous family) pre-
sented with collagen VI defects and broaden the phenotype
and complexity of collagen VI disorders [12].
Collagen VI expression can be analysed by labelling
muscle sections with antibodies to collagen VI (alone or
in combination with antibodies against a marker of the
basal lamina such as perlecan or collagen V) [1,13]. This
analysis is dependent on the availability of a muscle biopsy
in which the integrity of the basal lamina allows this
detailed study. In vitro analysis of collagen VI production
can also be studied in cultures of ﬁbroblasts, which are a
source of collagen VI production in skin and muscle [14].
The conventional analysis of collagen VI immunohisto-
chemistry in skin-derived ﬁbroblasts is, however, both a
laborious and non-quantitative technique which has limita-
tions when applied in diagnostic clinical settings [1].
Although the gold standard for the diagnosis of collagen
VI myopathy is sequencing of the COL6A1, COL6A2 and
COL6A3 genes, this technique is complicated by both the
large size of the three genes (107 coding exons in total)
and the high frequency of polymorphisms [8]. It is desir-
able, therefore, to have a robust system in place to ensure
that patients studied with genetic techniques have evidence
of collagen VI deﬁciency.
Flow cytometry analysis has been shown to be eﬀective in
various research applications. In the dysferlinopathies, for
example, the use of whole blood ﬂow cytometry has been
demonstrated to be a reliable, alternative diagnostic tool
for this muscular dystrophy which, like the collagen VI
myopathies, requires a diagnostic strategy preceding genetic
sequencing [15]. The use of ﬂow cytometry analysis has fur-
ther clinical applications in leukaemia, lymphoma and HIV
[16]. Speciﬁcally, the superiority of the ﬂow cytometry
technique in immunophenotyping of lymphomas in lymph
node biopsies has been illustrated, with ﬂow cytometry
signiﬁcantly more sensitive than frozen-section immunoper-
oxidase for demonstrating light-chain restriction [17]. Flow
cytometry analysis also has also had important applications
in skeletal muscle research, including its use in sorting satel-
lite cells from muscle ﬁbres [18] as well as muscle speciﬁc
proteins from murine muscle ﬁbres [19].
In this study we have investigated the potential value
of ﬂow cytometry analysis in assessing collagen VI expres-
sion in skin-derived ﬁbroblasts, as a screening method
prior to undertaking COL6A1, COL6A2 and COL6A3
gene sequencing.
2. Methods
2.1. Patients
A total of 13 collagen VI myopathy patients were
included in this study. Eight patients have a diagnosis ofUllrich congenital muscular dystrophy with conﬁrmed
mutations in COL6A1 (UCMD patients 7, 12 and 13),
COL6A2 (UCMD patients 8, 10 and 11) and COL6A3
(UCMD patients 6 and 9) genes. All of these UCMD cases
have been demonstrated to have abnormal collagen VI
expression by immunohistochemical staining of skin-
derived ﬁbroblast cultures Table 1 [1] [20]. The remain-
ing ﬁve patients have been diagnosed with Bethlem myop-
athy with conﬁrmed mutations in COL6A1, including a
father–son pair (BM 4 and 5). COL6A1, COL6A2 and
COL6A3 mutations in three patients were identiﬁed
using single condition ampliﬁcation/internal primer
(SCAIP) sequencing. These mutations have been
previously reported as part of a collaborative study [8]
(Table 1).
2.2. Skin biopsy and ﬁbroblast culture
Skin biopsies were taken from patients after obtaining
informed patient consent. Control skin biopsy samples
were obtained from paediatric patients (undergoing surgi-
cal procedures) with no known neuromuscular disease as
well as from adults with no known neuromuscular dis-
ease following written informed research consent. Fibro-
blasts were grown from skin explants and cultured in
Dulbecco’s modiﬁed Eagles medium (Invitrogen) supple-
mented with 20% foetal bovine serum (FBS, PAA), 1%
L-glutamine (Sigma) and 1% penicillin, streptomycin
and neomycin (Sigma). Cells were cultured at 37 C in
5% CO2.
2.3. Collagen VI immunostaining of ﬁbroblast cultures
105 cells were seeded onto clean coverslips coated with
ﬁbrillar collagen I solution (Purecol 5409, Nutacon).
When conﬂuent, the medium was changed to contain
50 lg/ml of L-ascorbic acid phosphate to allow for the
correct post-translational modiﬁcation and secretion of
collagen molecules. The medium was subsequently chan-
ged and ascorbic acid added every 2 days for 7 days’
duration. Cells were then ﬁxed with fresh 2% paraformal-
dehyde (pH adjusted to 7.4 ± 0.2) for 10 min. An aliquot
of cells was permeabilised with Triton X-100 (VWR,
0.05% in PBS) for 3 min. All cells were immunolabelled
with a monoclonal primary antibody against collagen VI
(MAB1944, Millipore) diluted in PBS/Triton or PBS
alone for 1 h (1/500) at room temperature. Coverslips
were washed 3 times with PBS (with or without Triton),
and anti-mouse biotinylated secondary antibody was
applied for 30 min (1/200, Amersham) at room tempera-
ture which was followed by washing with streptavidin-
conjugated Alexa 594 (1/1000, Invitrogen) for 15 min at
room temperature. Nuclei were stained with Hoescht
33342 (1/2000, Molecular Probes) for 5 min, and prepara-
tions were examined under a Leica DMR epiﬂuorescent
microscope linked to Metamorph software (Universal
Imaging).
Table 1
Clinical features and collagen VI molecular and biochemical status.
Patient BM1 BM2 BM3 BM4 BM5 UCMD6 UCMD7
Current age
(years)
47 39  42 7 16 21
Presentation Birth: hip dislocation 2 years Birth: hip
dislocation
Infancy Infancy:
hypotonia and
torticollis
Infancy: muscle
weakness and
progressive joint
contractures
Birth: hip
dislocation
Contractures Elbows: +
Knee: ++
Elbows: +++ Elbows: +++ Elbows:+++
Long ﬁnger
ﬂexors: +++
Achilles tendons:
+++
None Elbows: +++
Hips: +++
Knees: +++
Achilles tendons:
+++
Elbows:+++
Hips:+++
Knees:+++
Maximum
motor
ability
Independent
ambulation
Independent
ambulation
Independent
ambulation
Independent
ambulation.
Using walking
frame since age
40 years
Independent
ambulation
Independent
ambulation.
Wheelchair
dependence since
age 3.5 years
Independent
ambulation.
Wheelchair
dependence since
age 10 years
Respiratory
function: %
predicted
forced vital
capacity
(FVC)
Not available Not available FVC 70% (age
23 years)
Not available FVC 80% (age
6 years)
FVC 15% (age
9 years)
FVC 40% (age
12 years)
Mutation COL6A1: intron 3
G > A + 1, causing
the activation of a
cryptic donor splice
site in exon 3,
resulting in an in-
frame 66 nucleotide
deletion
Heterozygous
Gly341Val in
exon 14 of
COL6A1
Heterozygous
mutation
resulting in
skipping of exon
14 of COL6A1
Heterozygous
c.877G > A;
p.Gly293Arg in
exon 10 of
COL6A1
Heterozygous
c.877G > A;
p.Gly293Arg in
exon 10 of
COL6A1
Heterozygous
c.6210 + 1G > A
in intron 16 of
COL6A3
Homozygous
c.1776 + 1G > A
in intron 27 of
COL6A1
Muscle
collagen VI
double
immuno-
labelling
Muscle not available Muscle not
available
Reduced at the
sarcolemma
Muscle not
available
Muscle not
available
Reduced at the
sarcolemma
Muscle not
available
Fibroblast
collagen VI
immuno-
labelling
Moderate
reduction in the
ECM; increased
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction: **
Moderate
reduction in the
ECM; increased
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction: **
Moderate
reduction in the
ECM; increased
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction: **
Moderate
reduction in the
ECM; increased
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction: **
Marked
reduction in the
ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction:***
Marked
reduction in the
ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction:***
Marked
reduction in the
ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen
VI reduction:***
Flow
cytometry
result
41.2% 45.6% 28.1% 44.6% 50.5% 70.7% 60.0%
References [26,27] [1,8,9] [1,8]
(continued on next page)
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Table 1 (continued)
Patient UCMD8 UCMD9 UCMD10 UCMD11 UCMD12 UCMD13
Current age
(years)
19 15 30 8 23 9
Presentation 1.5 years Birth: hip dislocation
and hypotonia
1 year 1 year Birth: talipes Birth: talipes
Contractures Elbows: ++
Long ﬁnger ﬂexors: +
Knees: +
Achilles tendons:
+++
Elbows: ++
Hips: +++
Knees: +++
Elbows:+++
Hips: ++
Knees: +
Achilles tendons:
+++
Elbows: ++
Knees: +
Elbows: ++
Achilles tendons:
++
Elbows: ++
Hips: +
Knees: ++
Achilles tendons:
++
Maximum
motor
ability
Independent
ambulation.
Wheelchair
dependence since
age 11 years
Independent
ambulation.
Wheelchair
dependence since
6 years of age
Independent
ambulation.
Wheelchair
dependence since
age 15 years
Independent
ambulation.
Wheelchair
dependence since
age 8 years
Independent
ambulation. Part-time
wheelchair use since
age 18 years
Independent
ambulation.
Wheelchair
dependence since
age 8 years
Respiratory
function:
%
predicted
forced
vital
capacity
(FVC)
FVC 8% (age
15 years)
FVC 16% (age
12 years)
FVC 17% (age
19 years)
Not performed FVC 38% (age
18 years)
FVC 56% (age
7 years)
Mutation Homozygous
Cys777Arg in
exon 26 of COL6A2
Heterozygous donor
splice site change in
intron 16 of
COL6A3
Homozygous
c.2839_2850del;
p.Leu947_Gly950del
in exon 28 of
COL6A2
Homozygous
mutation
r.2839_2850del;
p.Leu947Gly950del
detected in exon 28
of the COL6A2 gene
Heterozygous
mutation r.868G>A;
p.Gly290Arg
detected in exon
10 of the COL6A1
gene
Heterozygous
mutation r.868G>C;
p.Gly290Arg
detected in exon
10 of the COL6A1
gene
Muscle
collagen
VI double
immuno-
labelling
Muscle not
available
Muscle not
available
Reduced at the
sarcolemma
Reduced at the
sarcolemma
Muscle not
available
Reduced at the
sarcolemma
Fibroblast
collagen
VI
immuno-
labelling
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Marked reduction in
the ECM; marked
intracellular
accumulation
following
permeabilisation.
Overall collagen VI
reduction: ***
Flow
cytometry
result
68.6% 65.9% 85.8% 72.5% 74.9% 68.8%
References [1,8] [1,8,9] [1,20] [1,20]
Flow cytometry results for controls (diﬀerence between permeabilised cells and non-permeabilised cells): 19.6–42.9%.
ECM = extracellular matrix.
+ = mild contractures (5–10).
++ = moderate contractures (>10 but <30).
+++ = severe contractures (>30).
* = mild collagen VI reduction in ECM.
** = moderate collagen VI reduction in ECM.
*** = marked collagen VI reduction in ECM.
 Deceased (died of lung cancer at age 30 years).
 Diﬀerence between permeabilised cells and non-permeabilised cells (= intracellular accumulation).
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Fig. 1a. Collagen VI production from ﬁbroblasts. Collagen VI immunolabelling of ﬁbroblast cultures illustrating the diﬀerent patterns of collagen VI
abnormalities. Fibroblasts were labelled with an antibody to collagen VI without permeabilisation (A, C and E) and with permeabilisation (B, D and F).
Control ﬁbroblasts (A and B) showed the normal extracellular network of collagen VI microﬁbrils with/without permeabilisation with no intracellular
accumulation when cells were permeabilised. Fibroblasts from a BM patient (BM4) showed a degree of reduction in collagen VI expression (C) with
moderate intracellular labelling in some cells following permeabilisation (D). Fibroblasts from a UCMD patient (UCMD7) showed signiﬁcant reduction
of collagen VI expression in the ECM (E). When cells were permeabilised (F) marked intracellular accumulation was seen in the vast majority of cells.
Nuclei were stained with Hoechst to control for cell density. (Scale bar = 25 lm).
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ﬁbroblasts
Primary skin ﬁbroblast cultures (standardised for passage
number and at a density of 8  105)were grown in 75 cm2 tis-
sue culture ﬂasks (BD). When cells were conﬂuent, 50 lg/ml
of L-ascorbic acid phosphate was added, and cells were fur-
ther incubated for 24 h. This time point was chosen because
in previous experiments we had shown that collagen VI was
already deposited in the extracellular matrix by this time
point, and the diﬀerences between control and patient cul-
tures could be readily detected (data not shown). Cells were
harvested with a non-enzymatic cell dissociation solution
(Sigma) and ﬁxed with 2% paraformaldehyde for 10 min
on ice. Afterwards, cells were washed with PBS (Mg2+ and
Ca2+ free, Invitrogen) containing 0.1%FBS and centrifuged.
Pellets were re-suspended and incubated with a monoclonal
primary antibody against collagen type VI (Millipore,
MAB1944, 1/250) in PBS/0.1% FBS or PBS/ 0.05% FBS
and Tween 20 (for permeabilisation) for 1 h. For a negative
control, cells were incubated without primary antibody on
ice. Cells were washed twice with or without 0.05% Tween
20 and then spun down at 3000g for 3 min. Rabbit anti-
mouse IgG conjugated to R.Phycoerythrin (RPE, Star12A,
SeroTec) was diluted (1/20) with either PBS/0.1% FBS orPBS/0.1% FBS and 0.05% Tween 20 for 20 min on ice. Cells
were thenwashed twice with PBS (with or without Tween 20,
as appropriate) and centrifuged at 3000g for 3 min. Finally,
cells were re-suspended in PBS/0.1% FBS and ﬁltered
through a 0.7 lmstrainer to ensure cells were separated indi-
vidually. Cells were then processed for ﬂow cytometry and
runon aCyanADP (BeckmanCoulter, California,USA) ﬁt-
ted with a 488 nm laser and a 633 nm red diode. Data anal-
ysis was done on Summit (Beckman Coulter, California,
USA) or Flowjo (TreeStar, Oregon, USA) software. A total
of 15,000 cells were analysed and gated using the two-param-
eter analysis side light scatter (SSC; linear scale) on the y-axis
and ﬂuorescence intensity (PE-collagen VI; log scale) on the
x-axis. Side scatter (SS) is related to the cellular cytoplas-
matic granularity and PE ﬂuorescence is collected with a
575 nm ± 12.5 band-pass ﬁlter (FL2 detector). A negative
control (where primary antibody is omitted) was used to
set up collagen VI positive immunolabelling gate and the
same gate was applied to all samples.2.5. Statistical analysis
Flow cytometry results from non-permeabilised and per-
meabilised cells are expressed asmean ± standard deviation.
Fig. 1b. Flow cytometry analysis. Flow cytometry analysis was performed in order to compare the outcome of two methods with the same ﬁbroblasts in
each category shown as (G–L) (G, I and K indicates without permeabilisation and H, J and L indicates following permeabilisation). A Total of 15,000 cells
were analysed and gated using the side scatter on the y-axis and ﬂuorescence intensity of collagen VI immunolabelling (PE-collagen VI) on the x-axis.
Immunolabelling of collagen VI positive gate was set up by negative control (where primary antibody is omitted). Control (G) showed approximately 73%
of non-permeabilised cells were positively labelled with collagen VI in ECM. While BM4 (I) showed mild collagen VI reduction (approximately 42%),
UCMD7 (K) showed severely decreased collagen VI expression in non-permeabilised cells (approximately 16%).
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2.12.0) to assess diﬀerences among the groups.
3. Results
The clinical features of all patients included in this study
are summarised in Table 1. Fibroblast cell cultures from all
13 patients had been tested previously and demonstrated
abnormal organisation of the collagen VI network [1]
(Fig. 1a). Regarding UCMD and BM patients for whom
muscle biopsy specimens were available, we observed
reduced collagen VI immunolabelling in the basal lamina,
as detailed in Table 1.
Prior to the ﬂow cytometry analysis, ﬁbroblasts were
examined under a Leica DMR epiﬂuorescent microscope
to conﬁrm that collagen VI was expressed on the cell sur-
face (data not shown). For ﬂow cytometry analysis, cells
were divided into three groups: a control group, a BMgroup (BM1–BM5) and an UCMD group (UCMD6–
UCMD13) (Fig. 1b). BM and UCMD groups were com-
pared to the control group (non-permeabilised cells)
(Fig. 2a).
The ﬁve control cell lines demonstrated a mean collagen
VI surface expression of 65.4 ± 10.7. When the control
cells were permeabilised, all demonstrated > 90% collagen
VI labelling, with a mean of 95.3 ± 2.2 reﬂecting the ability
of ﬂow cytometry to detect collagen VI both intracellularly
and on the cell surface (Fig. 2a). To assess intracellular
accumulation, these data were expressed as a diﬀerence
between permeabilised cells and non-permeabilised cells
(Fig. 2b).
Patient groups were compared to control groups. The
non-permeabilised cells demonstrated a marked reduction
of collagen VI surface expression (19.6 ± 10.0) in the
UCMD group compared to the control group (65.3 ±
10.7), with more than 1/3 reduction of collagen VI expres-
Fig. 2a. Quantiﬁcation of collagen VI expression in ﬁbroblasts determined by ﬂow cytometry. Patient groups were compared to control group with/
without permeabilisation. Collagen VI expression in non-permeabilised cells was the highest in the control group (just below 65%) compared to
approximately 54% in the BM group and approximately 20% in the UCMD group. (*=statistically signiﬁcant; p<0.001).
Fig. 2b. Quantiﬁcation of collagen VI intracellular retention as determined by ﬂow cytometry. The diﬀerence between permeabilised and non-
permeabilised cells was used to determine the level of intracellular retention of collagen VI. Collagen VI retention was deﬁnitively higher in the UCMD
group compared to the BM and control groups (p < 0.001). The BM group demonstrated less intracellular retention than the UCMD group; however, the
levels of retention did not always exceed control group levels (p < 0.05).
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collagen VI expression (54.1 ± 8.0) compared to the con-
trols, which, however, was not statistically signiﬁcant
(p < 0.1) (Fig. 2a).
When cells were permeabilised prior to staining, over
90% of cells were positive for collagen VI expression in
both patient groups as well as the control group. This
is in keeping with previous observations that in most
UCMD and in some BM ﬁbroblasts, the reduction in
extracellular collagen VI is accompanied by marked
intracellular accumulation of mutated collagen VI mole-
cules [1,21].Using the diﬀerence between permeabilised and non-
permeabilised cells, we noted a marked increase in collagen
VI intracellular accumulation in UCMD ﬁbroblasts
(70.9 ± 7.5%) relative to control ﬁbroblasts (30 ± 10.3%),
which was statistically signiﬁcant (p < 0.001). This conﬁrms
previous ﬁndings in UCMD using standard immunocyto-
chemical methods, which revealed reduced collagen VI
expression in the extracellular matrix in non-permeabilised
cells and the intracellular accumulation of collagen VI in
permeabilised cells [1]. We then analysed the diﬀerence
between permeabilised and non-permeabilised cells in the
BM group and found evidence of mildly increased intracel-
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when compared to controls was statistically signiﬁcant
(p < 0.05) (Fig. 2b).
Out of a total of 13 patient samples, all eight UCMD
cases showed clear reductions in collagen VI expression
in ﬁbroblasts with non-permeabilised cell collagen VI
expression ranging 9.7–36.8%, compared to control sam-
ples, which ranged between 50.0% and 76.9%. Among the
ﬁve BM cases, the reduction of collagen VI expression
was rather mild (44.8–66.2%) when compared to controls
(50.0–76.9%). Flow cytometry results of non-permeabilised
cells and diﬀerences between permeabilised and non-
permeabilised cells demonstrated decreased collagen VI
expression with increased levels of intracellular collagen
VI accumulation in UCMD and BM patients compared
to controls in all but one of the patients sampled (BM3).
4. Discussion
UCMD and BM are common forms of muscular dystro-
phies in childhood and, indeed, are the most common con-
genital muscular dystrophy variants in the UK population
(FM, personal observation). While the combination of
their characteristic clinical features and muscle imaging
ﬁndings often allows us to suspect these conditions, the
diagnostic pathway leading to the conﬁrmation of the
underlying genetic defect is prolonged, expensive and com-
plicated by the occurrence of both autosomal dominant
and autosomal recessive inheritance in each of the three
collagen VI genes (COL6A1, COL6A2 and COL6A3).
Further complicating this pathway is the high residual level
of collagen VI produced in BM. Arriving at a ﬁnal deﬁni-
tion of UCMD and BM at the genetic level is nevertheless
necessary to rule out other similar conditions, provide
accurate genetic counselling to families and will be neces-
sary to recruit patients in future clinical trials. A prerequi-
site for the genetic analysis of the 107 exons of the
COL6A1, COL6A2 and COL6A3 genes is the demonstra-
tion of abnormal collagen VI protein expression. While this
is straightforward in patients with UCMD, in whom mus-
cle biopsy often identiﬁes an abnormality, the biochemical
diagnostic process is complicated for those patients who
fall at the mild end of the collagen VI myopathy pheno-
typic spectrum with Bethlem myopathy. Indeed, dual
immunoﬂuorescence labelling of muscle biopsies (for colla-
gen VI and perlecan) is often apparently normal in BM
patients. Immunoﬂuorescence (IF) labelling of collagen
VI in skin ﬁbroblasts can demonstrate abnormalities in
BM, and in some series 78% of genetically conﬁrmed BM
patients were identiﬁed in this way [21]. This technique,
however, is labour-intensive, and the interpretation of bor-
derline IF labelling results subjective. In our experience, a
signiﬁcant proportion of BM patients show immunoﬂuo-
rescence labelling of ﬁbroblasts which is either normal or
only subtly increased intracellularly, which is not a speciﬁc
ﬁnding [1]. A more reproducible and more rapid method
for detecting the abnormal collagen VI expression inUCMD and BM would not only help to select patients
for subsequent molecular genetic analysis but could also
help to assign the pathogenic signiﬁcance of molecular
variants in the collagen VI genes.
Flow cytometry analysis is both a more sensitive and a
quantitative technique which has never been used before
for assaying collagen VI expression. In the present study
we performed ﬂow cytometry analysis and compared the
results with those results obtained from conventional immu-
noﬂuorescent labelling of ﬁbroblasts, using the same colla-
gen VI antibody and the same ﬁbroblast cell cultures.
Although this study was limited to 13 patients with geneti-
cally conﬁrmed collagen VI myopathies, ﬂow cytometry
analysis rapidly and clearly detected collagen VI deﬁciency
in all eight UCMD patients. These results suggest that ﬂow
cytometry analysis is highly sensitive in detecting severe col-
lagen VI deﬁciency, similar to what has been previously
demonstrated using conventional immunohistochemistry
[1,20,22]. In addition to conventional studies, ﬂow cytome-
try allowed us to precisely quantify the deﬁciency of collagen
VI in theUCMDpatients analysed as less than 1/3 of the lev-
els of collagen VI expressed in control ﬁbroblast samples.
In some BM patients ﬂow cytometry analysis detected a
reduction of collagen VI expression. This was not a consis-
tent ﬁnding, however, which accounts for the non-statistical
signiﬁcance of this testing in the BM group of patients. The
comparison of collagen VI expression in individual Bethlem
myopathy patients (non-permeabilised cells) compared to
controls demonstrated that three of the ﬁve BM patients
had clearly reduced collagen VI protein expression levels
(BM2 with 51.3%, BM4 with 51.3% and BM5 with 44.8%)
and one (BM1with 56.9%) hadmoderately reduced collagen
VI protein expression compared to our controls. One BM
patient’s collagen VI expression, however, was slightly
greater than the controls (BM3 with 66.2% versus control
average 65.3%). It is interesting to note that patients with
the same collagen VI mutation, for instance, patients BM4
and BM5 (father and son, respectively, with the same
COL6A1 heterozygous mutation) demonstrated compara-
ble ﬂow cytometry results (Table 1), once again conﬁrming
the robustness of this technical approach.
As ﬂow cytometry analysis oﬀers the ability to quantify
collagen VI expression, we looked to see if clinical severity
correlated with collagen VI expression level. When com-
paring the two diagnostic categories, there was a very good
discrimination of patients in the UCMD category with all
ﬂow cytometry results (non-permeabilised cells) below
37% and all BM patients with ﬂow cytometry results above
44%. These results suggest that ﬂow cytometry analysis
could be a useful tool when assigning disease severity in
young infants with collagen VI myopathies, before the
acquisition of motor milestones which may allow a conﬁ-
dent clinical diagnosis to be made. It is nevertheless impor-
tant to place any data obtained with laboratory techniques
within a clinical context.
In this study we demonstrate that ﬂow cytometry anal-
ysis can reliably quantify the deﬁciency of collagen VI
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were more variable and reﬂect the higher level of collagen
VI protein expression in these patients. Using non-
permeabilised cells in the BM group there was evidence
of a mild reduction of collagen VI expression when com-
pared to controls, which was not statistically signiﬁcant.
In individual BM patients, however, collagen VI expres-
sion values were in the lower range of what was observed
in control cells, suggesting that in a proportion of BM
patients ﬂow cytometry analysis may not be able to detect
a suﬃcient diﬀerence in collagen VI expression when com-
pared to control samples. This is not surprising, as mild
BM patients can have predominantly qualitative diﬀer-
ences in collagen VI network organisation [21], which
are not assessed by either the standard immunohistochem-
ical staining technique or the ﬂow cytometry analysis
technique. Therefore, care should be used when interpret-
ing a ﬂow cytometry result which does not demonstrate
clearly decreased collagen VI expression in patients with
suspected BM. In these patients additional studies on
ﬁbroblast immunolabelling techniques focused on the
assessment of subtle quantitative and qualitative diﬀer-
ences in collagen VI expression, might be required,
although they also have shortcomings such as subjectivity
of interpretation and lack of speciﬁcity of abnormalities
observed. Other studies including muscle magnetic
resonance imaging (MRI) could be incorporated into
the diagnostic repertoire in this group of patients, as this
imagining modality has been reported to detect
disease-speciﬁc imaging patterns in relation to genetic
diagnosis with a sensitivity of 90% and a speciﬁcity of
96% in a cohort of patients with muscular dystrophy
and spinal rigidity [23–25]. This analysis, however,
requires the collaboration of children, or the use of a
general anaesthetic in children below the age of 5 years.
Our results suggest that ﬂow cytometry analysis could
represent a useful technique for the rapid, quantitative
assessment of collagen VI expression in skin-derived ﬁbro-
blasts. In this capacity, ﬂow cytometry analysis could serve
as a screening test for collagen VI deﬁciency both to iden-
tify individuals in whom to initiate the molecular genetic
analysis or as a means to help assign pathogenicity of
genetic variants of unknown signiﬁcance.
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